A Phase 2 Multicenter Randomized Double-blind Placebo-controlled Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of TTI-101 in Participants with Idiopathic Pulmonary Fibrosis

Brief description of study

This multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical study is designed to evaluate the safety and tolerability of 3 dose levels of TTI-101 vs placebo in participants with idiopathic pulmonary fibrosis (IPF). Following a screening period of up to 28 days, 100 participants will be randomly assigned (1:1:1:1) to receive 1 of 3 dose levels of TTI-101 or matching placebo.

Clinical Study Identifier: s23-00399
Principal Investigator: Rany Condos.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.